Published in final edited form as:

Eur J Epidemiol. 2017 May ; 32(5): 419–430. doi:10.1007/s10654-017-0262-y.

Genetic variation in the *ADIPOQ* gene, adiponectin concentrations and risk of colorectal cancer – a Mendelian Randomization analysis using data from three large cohort studies

Katharina Nimptsch^{1,2}, Mingyang Song^{2,3,4,5}, Krasimira Aleksandrova⁶, Michail Katsoulis^{7,8}, Heinz Freisling⁹, Mazda Jenab⁹, Marc J. Gunter⁹, Konstantinos K. Tsilidis^{10,11}, Elisabete Weiderpass^{12,13,14,15}, H Bas Bueno-De-Mesquita^{10,16,17}, Dawn Q Chong^{4,5,18}, Majken K. Jensen^{2,19}, Chunsen Wu^{20,21,22}, Kim Overvad²⁰, Tilman Kühn²³, Myrto Barrdahl²³, Olle Melander²⁴, Karin Jirström²⁴, Petra H. Peeters^{25,26}, Sabina Sieri²⁷, Salvatore Panico²⁸, Amanda J. Cross¹⁰, Elio Riboli¹⁰, Bethany Van Guelpen²⁹, Robin Myte²⁹, José María Huerta^{30,31}, Miguel Rodriguez-Barranco^{31,32}, José Ramón Quirós³³, Miren Dorronsoro³⁴, Anne Tjønneland³⁵, Anja Olsen³⁵, Ruth Travis³⁶, Marie-Christine Boutron-Ruault^{37,38}, Franck Carbonnel^{37,38,39}, Gianluca Severi^{37,38,40,41}, Catalina Bonet⁴², Domenico Palli⁴³, Jürgen Janke¹, Young-Ae Lee⁴⁴, Heiner Boeing⁴⁵, Edward L. Giovannucci^{2,3,19}, Shuji Ogino^{3,19,46,47}, Charles S. Fuchs^{19,46}, Eric Rimm^{2,3,19}, Kana Wu², Andrew T. Chan^{4,5,19,48}, and Tobias Pischon^{1,49}

¹Molecular Epidemiology Research Group, Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany ²Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA ³Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA ⁴Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA ⁵Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA ⁶Nutrition, Immunity and Metabolism Start-up Lab, Department of Epidemiology, German Institute of Human Nutrition (DIfE), Potsdam-Rehbruecke, Nuthetal, Germany ⁷Hellenic Health Foundation, Athens, Greece ⁸Farr Institute of Health Informatics Research at London, UCL, London, UK ⁹International Agency for Research on Cancer (IARC-WHO), Lyon, France ¹⁰Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom ¹¹Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece ¹²Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway ¹³Department of Research, Cancer Registry of Norway, Oslo, Norway ¹⁴Department of Medical

Corresponding author: Dr. Katharina Nimptsch, Molecular Epidemiology Research Group, Max Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Straße 10, 13125 Berlin, Tel.: ++49 30/9406 – 4573, Fax: ++49 30/9406 – 4576, katharina.nimptsch@mdc-berlin.de.

Potential conflict of interest

Andrew T. Chan declared consultancies for Bayer Healthcare and Pfizer Inc. Ruth Travis declared salary and support for EPIC-Oxford from Cancer Research UK (paid by the University of Oxford), support for prostate cancer research project on metabolomics from the World Cancer Research Fund as well as support for EPIC-Oxford from the UK Medical Research Council. All other authors declared no potential conflict of interest.

Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden ¹⁵Samfundet Folkhälsan, Helsinki, Finland ¹⁶Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands ¹⁷Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia ¹⁸Division of Medical Oncology, National Cancer Centre Singapore, Singapore ¹⁹Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA ²⁰Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark ²¹Institute of Clinical Research, University of Southern Denmark ²²Odense University Hospital, Denmark ²³Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany ²⁴Department of Clinical Sciences Lund, Lund University, Malmö, Sweden ²⁵Dept of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands ²⁶MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, UK ²⁷Epidemiology and Prevention Unit Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy ²⁸Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy ²⁹Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden ³⁰Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain ³¹CIBER Epidemiología y Salud Pública (CIBERESP), Spain ³²Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain ³³Public Health Directorate, Asturias, Spain ³⁴Public Health Direction and Biodonostia Research Institute- Ciberesp, Basque Regional Health Department, San Sebastian Spain ³⁵Danish Cancer Society Research Center, Copenhagen, Denmark ³⁶Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK ³⁷Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France ³⁸Gustave Roussy, F-94805, Villejuif, France ³⁹Department of Gastroenterology, Assistance Publique-Hôpitaux de Paris (AP-HP), University hospitals Paris-Sud, Site de Bicêtre, Paris Sud University, Paris XI, Le Kremlin Bicêtre, Villejuif, France ⁴⁰Human Genetics Foundation (HuGeF), Torino, Italy ⁴¹Cancer Council Victoria and University of Melbourne, Australia ⁴²Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Barcelona, Spain ⁴³Cancer Research and Prevention Institute (ISPO) Florence, Italy ⁴⁴Genetics of Allergic Disease Research Group, Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany ⁴⁵Department of Epidemiology, German Institute of Human Nutrition (DIfE), Potsdam-Rehbruecke, Nuthetal, Germany ⁴⁶Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA ⁴⁷Division of MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA ⁴⁸Broad Institute, Cambridge, Massachusetts, USA ⁴⁹Charité Universitätsmedizin, Berlin, Germany

Abstract

Higher levels of circulating adiponectin have been related to lower risk of colorectal cancer in several prospective cohort studies, but it remains unclear whether this association may be causal. We aimed to improve causal inference in a Mendelian Randomization meta-analysis using nested

case-control studies of the European Prospective Investigation into Cancer and Nutrition (EPIC, 623 cases, 623 matched controls), the Health Professionals Follow-up Study (HPFS, 231 cases, 230 controls) and the Nurses' Health Study (NHS, 399 cases, 774 controls) with available data on pre-diagnostic adiponectin concentrations and selected single nucleotide polymorphisms (SNPs) in the *ADIPOQ* gene. We created an *ADIPOQ* allele score that explained approximately 3% of the interindividual variation in adiponectin concentrations. The *ADIPOQ* allele score was not associated with risk of colorectal cancer in logistic regression analyses (pooled OR per score-unit 0.97, 95% CI 0.91, 1.04). Genetically determined two-fold higher adiponectin was not significantly associated with risk of colorectal cancer using the *ADIPOQ* allele score as instrumental variable (pooled OR 0.73, 95% CI 0.40, 1.34). In a summary instrumental variable analysis (based on previously published data) with higher statistical power, no association between genetically determined two-fold higher adiponectin and risk of colorectal cancer was observed (0.99, 95% CI 0.93, 1.06 in women and 0.94, 95% CI 0.88, 1.01 in men). Thus, our study does not support a causal effect of circulating adiponectin on colorectal cancer risk. Due to the limited genetic determination of adiponectin, larger Mendelian Randomization studies are necessary to clarify whether adiponectin is causally related to lower risk of colorectal cancer.

Keywords

adiponectin; *ADIPOQ*; colorectal cancer; Mendelian Randomization

Background

Obesity, in particular abdominal obesity is an established risk factor for the development of colorectal cancer (1). Although the underlying biological mechanisms have not been fully elucidated, it is widely accepted that the adipose tissue, particularly visceral adipose tissue, is an active endocrine organ secreting various bioactive substances collectively named adipokines, which may provide an important link between body fatness and colorectal cancer risk (2). In contrast to many other adipokines, adiponectin expression is suppressed in obesity and plasma concentrations are lower in obese than in lean individuals (3). Adiponectin has been suggested to play a protective role in the development of cancer either directly through inhibition of cell growth (e.g. via RAS signaling (4)) and induction of apoptosis, or indirectly through improved insulin sensitivity and reduced inflammation (5). The association between circulating adiponectin concentrations and risk of colorectal cancer has been investigated in several prospective cohort studies, with mixed findings: Higher plasma adiponectin concentrations were associated with lower risk of colorectal cancer (slightly stronger in women than men, but no statistically significant sex-differences) in the European Prospective Investigation into Cancer and Nutrition (EPIC) (6) and in the Health Professionals Follow-up study (HPFS), while no association was observed in the Nurses' Health Study (NHS) (7). A meta-analysis of ten case-control or nested case-control studies (not including the data from EPIC, NHS or HPFS) reported a statistically significant two percent lower risk of colorectal cancer or adenoma for a 1 µg/mL increment in adiponectin in men whereas among women no association was observed (8).

To date, it remains unclear whether adiponectin plays a causal role in the development of colorectal cancer not least because it cannot be excluded that residual confounding and/or reverse causation bias might have introduced bias in observational associations (Figure 1). Mendelian Randomization is a statistical approach that can improve causal inference (9). The principle is that under the assumption of the random assortment of alleles at conception, genetic variants that are associated with biomarker levels can be used as relatively unbiased proxies for biomarker concentrations due to two advantages. First, since the genotype of an individual is determined at gamete formation and cannot be altered later on (e.g. by disease onset), there is no possibility of reverse causation (10). Second, the relationship between genetic variants and disease risk can be assumed to be not confounded by lifestyle and behavioral factors that can confound the observed association between circulating biomarkers and risk of disease. Therefore, using genetic variants associated with circulating biomarker concentrations in a Mendelian Randomization approach may provide insight into the underlying causal relationships by circumventing reverse causation and residual confounding. In a pooled analysis from the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), which includes data from NHS, HPFS and eight other studies comprising overall more than 7,000 colorectal cancer cases and approximately the same number of controls, genetic variants in the gene encoding adiponectin (*ADIPOQ*) were not associated with colorectal cancer risk (11). However, a simultaneous analysis of adiponectin concentrations, *ADIPOQ* genetic variants and colorectal cancer was not conducted, because adiponectin plasma levels were only available in a subset of included studies, namely NHS and HPFS. With a dataset including individual participant data on genetic variants, biomarker concentration and disease outcome, a traditional Mendelian Randomization analysis taking into account the actual strength of the association between *ADIPOQ*-SNPs and adiponectin concentrations in the study population can be performed, which has the advantage that instrumental variable assumptions can be directly assessed (12, 13). The aim of our investigation was therefore to improve causal inference in the association between circulating adiponectin and colorectal cancer risk using *ADIPOQ* genetic variants in a Mendelian Randomization meta-analysis with individual participant data from the EPIC, HPFS and NHS cohorts.

Methods

Study population

The three studies included in the present investigation were all nested case-control studies of large prospective cohorts with long follow-up. In all nested case-control studies, colorectal cancer was defined according to the International Statistical Classification of Diseases, Injury and Causes of Death (ICD-10) as cancers of the colon (C18.0–C18.7), cancers of the rectum (C19–C20) and tumors that were overlapping or unspecified (C18.8–C18.9). Blood samples were collected prior to diagnosis and matched control participants were selected using incidence density sampling, i.e. selection was performed among study participants who were alive and free of cancer (except non-melanoma skin cancer) at the time of diagnosis of the colorectal cancer case.

The EPIC study is a large multicenter prospective cohort including more than 520,000 study participants from 10 European countries who were aged between 35 and 70 years at recruitment which took place from 1992 to 2000(14). Baseline examinations included anthropometric measurements, standardized ascertainment of lifestyle characteristics and medical history information as well as collection of blood samples. The EPIC study was approved by the ethical review board of the International Agency for Research on Cancer (IARC, Lyon, France) and the institutional review boards of each participating study center and informed consent was obtained from all participants. Incident cancer cases including colorectal cancer cases were determined through record linkage with local cancer registries in most countries (Denmark, Italy (except Naples), the Netherlands, Norway, Spain, Sweden, United Kingdom, complete up to 2003). In some countries (France, Germany, Italy (Naples), Greece, complete up to 2002) active follow-up was organized by contact of participants or next of kin through mailed questionnaires, followed by verification of self-reported cases by study physicians using health insurance data, data from cancer and clinical registries as well as medical records provided by the treating physicians. In the present analysis, colorectal cancer cases with available prediagnostic blood samples and DNA were included. As has been described previously (6), the nested case-control design matched each case to one control using incidence density sampling. Control participants were selected matched on age at blood collection (2 months to 4-year intervals), study center, fasting status (<3, 3–6, or >6 hours) as well as menopausal status and hormone use in women. The nested case-control study was designed to be applicable for several biomarker studies, which explains inclusion of the latter matching criteria which were not relevant for the present analysis. The number of cases and matched controls included in the present study is 1,246 (623 cases, 623 matched controls) which is 52% of the study size of the previous analysis on circulating adiponectin and risk of colorectal cancer in EPIC (1,206 cases, 1,206 matched controls) (6). This difference is largely explained by unavailability of DNA samples from the Danish EPIC centers due to local technical and organizational issues.

The HPFS and NHS are two large US cohort studies, detailed descriptions of which are provided elsewhere (15, 16). In brief, the HPFS started in 1986, including 51,529 men aged 40–75 years, and the NHS started in 1976 and included 121,701 women aged 30–55 years. In both cohorts, study participants provided information on medical history and lifestyle at recruitment. Since then, follow-up questionnaires were administered biennially to collect and update medical and lifestyle information and to elicit medical diagnoses. The follow-up rates in both cohorts exceeded 90% in each 2-year cycle and the cumulative follow-up rate (percentage of potentially collected person-years) was 94% in HPFS and 93% in NHS. Blood specimens were provided by 18,225 HPFS participants (35%) between 1993 and 1995 and by 32,826 NHS participants (27%) between 1989 and 1990 by overnight courier. Details on the procedures of blood collection as well as handling and storage of blood samples have been described previously(17, 18). Among the participants for whom blood samples and DNA were available, 231 colorectal cancer cases were confirmed after blood collection in HPFS (up to January 1st 2008) and 399 in NHS (up to October 1st 2008). For each case up to two controls were randomly selected using incidence density sampling. The majority of individuals included in the nested case-control studies were of Caucasian ancestry in both HPFS (95.5%) and NHS (99.9%). All study participants provided informed consent and the

study protocol was approved by the Institutional Review Board of the Brigham and Women's Hospital and the Harvard T.H. Chan School of Public Health. The total number of participants in the present investigation is 2,880 (1,253 cases and 1,627 controls), including 1,246 in EPIC (623 cases and 623 controls), 461 in HPFS (231 cases, 230 controls) and 1,173 in NHS (399 cases, 774 controls).

Adiponectin measurement

Total circulating adiponectin concentration was measured using enzyme-linked immunosorbent assays from ALPCO Diagnostics (Salem, New Hampshire) in the three studies (6, 7). Based on quality control samples, interbatch coefficients of variation were 8.3% in EPIC and 8.6% in HPFS and NHS. Adiponectin measurements in $n=300$ paired samples from HPFS showed high reliability, with intraclass correlation coefficient of 0.85 when measured within the same persons one year apart (19).

SNP selection and genotyping

In EPIC, a set of tagging SNPs covering variations in the *ADIPOQ* gene in populations of European ancestry was selected using HapMap 22/phase II CEPH population data (Utah residents with northern and western European descent) applying stringent criteria (minor allele frequency $>5\%$ and pairwise $r^2 \geq 0.8$). A total number of 15 SNPs were genotyped using TaqMan methodology (genotype call rates $>99.2\%$ for all the assays), of which one (rs7649121) was not in Hardy-Weinberg equilibrium in control participants ($p<0.0001$) and therefore was excluded from analysis. In HPFS and NHS SNPs in the *ADIPOQ* gene were selected based on previous evidence from genome-wide association studies (GWAS) on circulating adiponectin concentrations (20–23). Additional SNPs in adiponectin-related genes that have been associated with colorectal cancer risk were genotyped (24–26). A total of 19 SNPs were genotyped using Illumina HumanOmniExpress as part of the GECCO project (11). Missing SNPs were imputed to HapMap II release 24. All genotyped SNPs were in Hardy-Weinberg equilibrium in control participants. Eight *ADIPOQ* SNPs were available in all three included studies (rs1063539, rs16861194, rs822394, rs17300539, rs17366568, rs17366743, rs266729, rs1501299) and minor allele frequencies were comparable.

Statistical analysis

We created an *ADIPOQ* allele score which was used to derive Mendelian Randomization estimates in two different approaches: Firstly, we analyzed the *ADIPOQ* allele score in relation to colorectal cancer risk. Secondly, we applied an instrumental variable approach, simultaneously incorporating the *ADIPOQ* allele score and plasma adiponectin concentrations, to model the association between genetically determined circulating adiponectin and colorectal cancer risk. While the first approach, which is considered as an equivalent to the intention-to-treat analysis in a randomized controlled trial (27), can only test for the existence of a causal association, the second approach aims at estimating the magnitude of a causal association (e.g. risk estimate per 2-fold higher genetically determined adiponectin) (28).

ADIPOQ allele score

The weighted *ADIPOQ* allele score was constructed by summing alleles that have been associated with higher adiponectin with genome-wide significance in a previous meta-analysis of GWAS on adiponectin levels, using their GWAS-coefficients as weights (20). Only SNPs not highly correlated ($r^2 < 0.8$) were included in the score. For NHS and HPFS, the included SNPs were rs17300539, rs17366568, rs266729, rs1501299 and rs6810075. The score in EPIC was built using the same SNPs, except that for rs6810075 the proxy SNP rs182052 was used. To examine whether the *ADIPOQ* allele score is independent of potentially confounding factors, we compared baseline characteristics in each study across score categories (approximate tertiles).

The associations between the individual *ADIPOQ* SNPs as well as the weighted *ADIPOQ* allele score and adiponectin concentrations were examined using linear regression models with robust variance in control participants (29). Adiponectin concentrations were naturally log-transformed (because of skewed distribution) and we calculated the estimated relative change in percent in adiponectin per minor allele (with genotypes coded 0, 1 or 2 according to the number of variant alleles) or per score unit, respectively. In addition, R^2 and F-values as measures of instrument strength are presented. In the previous publication by Song et al. (11) the association between *ADIPOQ* SNPs and plasma adiponectin concentrations was presented for HPFS and NHS, but the here included colorectal cancer controls were only a small subset of the individuals included in that analysis.

Association between ADIPOQ allele score and colorectal cancer

The association between the *ADIPOQ* allele score (per score-unit) in relation to risk of colorectal cancer was calculated in each study. In EPIC, we used conditional logistic regression conditioning on the matching variables and calculating odds ratios (ORs) and 95% confidence intervals that approximate incidence rate ratios and can be interpreted as relative risks. In HPFS and NHS, we used unconditional logistic regression adjusted for matching variables (age at blood draw and date of blood draw) to estimate relative risks. In sensitivity analyses, we restricted the logistic regression models to individuals with Caucasian ancestry (n=16 excluded in HPFS and n=1 excluded in NHS). Because multivariable adjustment is per definition not required in Mendelian Randomization studies, only minimally adjusted (conditional logistic regression conditioned on the matching variables or unconditional logistic regression adjusted for matching factors) estimates are presented. We pooled the study-specific results using a meta-analytic approach with random effects (30), thereby also assessing potential heterogeneity across studies.

Instrumental variable analysis

For the joint analysis of adiponectin concentrations, genetic variants of the *ADIPOQ* gene and colorectal cancer risk, we performed an instrumental variable analysis using two-stage regression. In the first stage, adiponectin concentrations were predicted based on the *ADIPOQ* allele score by means of linear regression. In order to avoid potential bias (31), the first stage regression was performed only in control participants and genetically determined adiponectin was predicted for the total study population including participants without measured adiponectin. In the second stage, a logistic regression of colorectal cancer on the

predicted adiponectin concentrations was performed in each study. In EPIC, the second stage was a conditional logistic regression appropriate for the matched design, whereas in HPFS and NHS, the second stage was an unconditional logistic regression adjusted for matching factors. For HPFS and NHS, we restricted instrumental variable analyses to individuals of Caucasian ancestry in sensitivity analyses. The risk estimates resulting from the instrumental variable analysis display the association between 2-fold genetically determined higher adiponectin in relation to risk of colorectal cancer. Pooled associations were determined using random effects model and potential heterogeneity was assessed. We performed over-identification tests to evaluate whether the Mendelian Randomization estimates are of similar magnitude across the multiple genetic instruments (i.e. individual SNPs included in the *ADIPOQ* allele score) (28). Finally, to increase statistical power, we performed a summary instrumental variable analysis using published data on genetic associations with adiponectin and colorectal cancer in a likelihood-based approach (13). Parameters for the association between the SNPs included in the *ADIPOQ* allele score and circulating adiponectin were taken from GWAS data (20) and parameters for the association between the SNPs and colorectal cancer were derived from the analysis in GECCO (11). Because summary instrumental variable analysis can be biased when correlated SNPs are included (13), we omitted rs266729 from this analysis, because it is in linkage disequilibrium with rs6810075 ($r^2=0.5$).

All statistical tests are two-sided with significance at the 5% level. Instrumental variable analyses were performed using the STATA SE 12 (StataCorp, College Station, Texas, USA). Summary instrumental variable analyses were performed with a publicly available R-Studio application (Foundation for Statistical Computing, Vienna, Austria). All other analyses were performed using SAS (for EPIC data: SAS Enterprise Guide 4.3; for HPFS and NHS data: SAS 9.3; SAS Institute Inc., Cary, North Carolina, USA).

Results

Baseline characteristics of study participants in EPIC, HPFS and NHS are displayed in Table 1. In EPIC and HPFS, incident colorectal cancer cases had statistically significantly higher body mass index (BMI) and waist circumference than controls at baseline, whereas in NHS, these anthropometric measures did not differ between case and control participants. In EPIC, colorectal cancer cases consumed more alcohol and red and processed meat than control participants, whereas in the US cohorts, no such differences were observed. Other potentially confounding factors including physical activity and fiber intake did not differ remarkably between cases and controls in any study. In EPIC and HPFS, but not in NHS, adiponectin concentrations were lower in cases than in control participants in univariate comparisons.

Of the 14 *ADIPOQ* SNPs available for analysis in EPIC, five SNPs were statistically significantly associated with circulating adiponectin (Table 2). Each unit of the GWAS-based *ADIPOQ* allele score was associated with 6.5 % (95% CI 3.6, 9.4) higher adiponectin. The *ADIPOQ* allele score explained 3.2% of the interindividual variation in adiponectin concentrations (F-value 20.2). In HPFS, three of the 19 genotyped SNPs were statistically significantly associated with adiponectin concentrations (Table 3). Each unit of the *ADIPOQ*

allele score was associated with 7.7 % (95% CI 0.9, 14.9) higher adiponectin (F-value 5.0). In NHS, six of the 19 available SNPs were statistically significantly associated with circulating adiponectin. The *ADIPOQ* allele score was associated with 7.7 % (95% CI 4.1, 11.3) higher adiponectin concentrations and explained 3.6% of the interindividual variation in circulating adiponectin (F-value 18.8).

Potentially confounding factors assessed in the three cohorts did not differ remarkably across categories (approximate tertiles) of the *ADIPOQ* allele score (all P-values >0.05, supplemental table 1).

The *ADIPOQ* allele score was not statistically significantly associated with risk of colorectal cancer (pooled OR per score-unit 0.97, 95% CI 0.91, 1.04) in logistic regression analysis (table 4). This result was not altered when logistic regression analyses were restricted to Caucasian individuals in HPFS and NHS (pooled OR 0.97, 95% CI 0.91, 1.04). In the instrumental variable analysis taking measured adiponectin and *ADIPOQ* genetic variation in our study population simultaneously into account (table 5), using the *ADIPOQ* allele score as instrumental variable, genetically determined two-fold higher adiponectin was not statistically significantly associated with lower risk of colorectal cancer (pooled OR 0.73, 95% CI 0.40, 1.34). These associations were not altered by restriction to Caucasians in HPFS and NHS (pooled OR 0.73, 95% CI 0.41, 1.33). Over-identification tests suggested that the Mendelian Randomization estimates for colorectal cancer risk were similar across the individual SNPs included in the *ADIPOQ* allele score (P-values testing the null-hypothesis of identical effects across instruments were 0.64 in EPIC, 0.81 in HPFS and 0.52 in NHS).

In the summary instrumental variable analysis using published data, no association between genetically determined higher adiponectin and risk of colorectal cancer was observed (OR per 2-fold higher adiponectin 0.99, 95% CI 0.93, 1.06 in women and 0.94, 95% CI 0.88, 1.01 in men) using the four SNPs rs1730539, rs17366568, rs1501299 and rs6810075 as instrumental variables.

Discussion

In this Mendelian Randomization analysis using data from three nested case-control studies of large prospective cohorts, we did not find evidence for a causal contribution of high adiponectin levels to lower risk of colorectal cancer. However, adiponectin concentrations were genetically determined only to a limited extent, which limited statistical power for our Mendelian Randomization analysis.

In a genetic association meta-analysis, the minor alleles of three *ADIPOQ* SNPs (rs1501299, rs2241766, rs266729) were associated with colorectal cancer risk (32), but associations were only seen in Asians and not in Caucasians. Individual SNPs at the *ADIPOQ* loci (rs17300539, rs17366568, rs17366743, rs1501299, rs3774261 (the proxy SNPs rs2241766 was used in GECCO), rs6810075, rs266729, rs6773957, rs6444175, rs1063538), including those incorporated in the *ADIPOQ* allele score in the present study, were unrelated to risk of colorectal cancer in GECCO (11). In the same study, the allele-sum of 16 SNPs that have

been related to higher adiponectin concentrations in previous GWAS were combined in a genetic score, which was not related to colorectal cancer risk in women (OR per ten-allele increment 1.08, 95% CI 0.95, 1.22) or men (OR 1.01, 95% CI 0.90, 1.13). In contrast, in a two-sample Mendelian Randomization meta-analysis (33) using the *ADIPOQ* SNP rs2241766 as instrumental variable, 1 mg/L genetically determined higher adiponectin was associated with a 20–40% higher risk of colorectal cancer.

The strength of our study is the ability to jointly investigate adiponectin, genetic variation in the *ADIPOQ* gene and risk of colorectal cancer. In contrast to a two-sample Mendelian Randomization design, a full sample design, where genetic information and intermediate phenotype data (i.e. measured adiponectin concentration) are available in the same study participants, generally requires less assumptions and allows for systematic evaluation of instrumental variable assumptions (34). Thus, we were able to estimate the strength of the association between the *ADIPOQ* SNPs as well as the *ADIPOQ* allele score and adiponectin concentrations in our sample, thereby showing that the first Mendelian Randomization assumption was fulfilled. Furthermore, we showed that potentially confounding lifestyle factors did not vary substantially across categories of the instrumental variable, i.e. the second Mendelian Randomization assumption was also satisfied (35). It should be noted that only potentially confounding factors measured in the three studies could be investigated, thus, it cannot be entirely excluded that unmeasured confounders varied by categories of the *ADIPOQ* allele score. Assessment of the third Mendelian Randomization assumption (instrumental variable is associated with the outcome only through the intermediate exposure of interest, i.e. no pleiotropy) is not as straightforward, but the use of multiple SNPs as instrumental variables argues against unknown pleiotropy if the Mendelian Randomization estimates are similar across the multiple independent instruments, which was confirmed in our samples by the non-significant over-identification test results. Furthermore, the genetic variants used as instrumental variables were restricted to the *ADIPOQ* gene and therefore likely act directly on the adiponectin trait, which argues also against pleiotropic effects (27).

However, our study has also several limitations: Given the limited genetic determination of adiponectin concentrations, our sample sizes from three nested case-control studies of prospective cohorts was limited to derive robust causal estimates. The *ADIPOQ* allele score applied here explained only a low proportion (2.9%–3.6%) of the interindividual variation in adiponectin concentrations. With this genetic instrument and our sample size, the minimal OR that could have been detected with 80% statistical power was 0.61 per standard deviation in adiponectin, which is a stronger association than has been observed in most observational studies (8). Even with the relatively large sample size in GECCO (7,020 cases, 7,631 controls) no association between a genetic score of variants associated with adiponectin and colorectal cancer was detected (11). Furthermore, in our summary data instrumental variable analysis, genetically determined higher adiponectin was not associated with colorectal cancer risk (minimal detectable OR with 80% power: 0.76 per standard deviation in adiponectin). A much larger sample size (n=33,960 cases, 33,960 controls) would be necessary to detect a moderate effect (e.g. OR 0.89 per 1 SD as observed in EPIC (6)) of adiponectin and colorectal cancer. Therefore, with our study and the summary instrumental variable analysis based on GECCO, we cannot rule out causality in the

association between circulating adiponectin and risk of colorectal cancer. Although it has been suggested that the 2-stage instrumental variable estimator may result in biased estimates under case-control sampling, it has been shown to be unbiased under the null hypothesis of no causal effect as in the present study (36).

In conclusion, this Mendelian Randomization meta-analysis using individual data from three nested case-control studies of prospective cohorts does not support a causal effect of circulating adiponectin on colorectal cancer risk. This lack of association may be related to the limited genetic determination of adiponectin and the limited sample size. Therefore, larger Mendelian Randomization studies are necessary to clarify whether adiponectin is causally related to lower risk of colorectal cancer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Éducation Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada; PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236), and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). Measurement of biomarkers in EPIC was partly supported by World Cancer Research Fund International and Wereld Kanker Onderzoek Fonds (WCRF NL). The research based on the Nurses' Health Study and the Health Professional Follow-up Study are financially supported by U.S. NIH grants [P01 CA87969, UM1 CA186107, R01 CA49449 (to NHS), P01 CA55075, UM1 CA167552 (to HPFS), P50 CA127003 (to C.S. Fuchs), R01 CA151993, R35 CA197735 (to S. Ogino), K24 DK098311 and R01 CA137178 (to A.T. Chan)]. A.T. Chan is a Damon Runyon Clinical Investigator. We would like to thank the participants and staff of the Nurses' Health Study and Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

References

1. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Colorectal Cancer. Washington, DC: 2011. Continuous Update Project Report.
2. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nature reviews Immunology*. 2006; 6(10):772–83. DOI: 10.1038/nri1937
3. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? *Diabetes care*. 2003; 26(8):2442–50. [PubMed: 12882876]
4. Inamura K, Song M, Jung S, et al. Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. *Journal of the National Cancer Institute*. 2016; 108(4)doi: 10.1093/jnci/djv363

5. Kim AY, Lee YS, Kim KH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. *Mol Endocrinol*. 2010; 24(7):1441–52. DOI: 10.1210/me.2009-0498 [PubMed: 20444885]
6. Aleksandrova K, Boeing H, Jenab M, et al. Total and high-molecular weight adiponectin and risk of colorectal cancer: the European Prospective Investigation into Cancer and Nutrition Study. *Carcinogenesis*. 2012; 33(6):1–8. DOI: 10.1093/carcin/bgs133
7. Song M, Zhang X, Wu K, et al. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. *Cancer prevention research (Philadelphia, Pa)*. 2013; 6(9):875–85. DOI: 10.1158/1940-6207.CAPR-13-0169
8. Xu XT, Xu Q, Tong JL, et al. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. *Journal of digestive diseases*. 2011; 12(4):234–44. DOI: 10.1111/j.1751-2980.2011.00504.x [PubMed: 21791018]
9. Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? *International journal of epidemiology*. 2003; 32(1):1–22. [PubMed: 12689998]
10. Ebrahim S, Davey Smith G. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? *Human genetics*. 2008; 123(1):15–33. DOI: 10.1007/s00439-007-0448-6 [PubMed: 18038153]
11. Song M, Gong J, Giovannucci EL, et al. Genetic variants of adiponectin and risk of colorectal cancer. *International journal of cancer*. 2014; doi: 10.1002/ijc.29360
12. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. *American journal of epidemiology*. 2013; 178(7):1177–84. DOI: 10.1093/aje/kwt084 [PubMed: 23863760]
13. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genetic epidemiology*. 2013; 37(7):658–65. DOI: 10.1002/gepi.21758 [PubMed: 24114802]
14. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr*. 2002; 5(6B):1113–24. [PubMed: 12639222]
15. Colditz GA, Manson JE, Hankinson SE. The Nurses’ Health Study: 20-year contribution to the understanding of health among women. *Journal of women’s health/the official publication of the Society for the Advancement of Women’s Health Research*. 1997; 6(1):49–62.
16. Rimm EB, Giovannucci EL, Willett WC, et al. Prospective study of alcohol consumption and risk of coronary disease in men. *Lancet*. 1991; 338(8765):464–8. [PubMed: 1678444]
17. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. *Journal of the National Cancer Institute*. 2005; 97(22):1688–94. DOI: 10.1093/jnci/dji376 [PubMed: 16288122]
18. Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. *Journal of the National Cancer Institute*. 1995; 87(17):1297–302. [PubMed: 7658481]
19. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. *Clinical chemistry*. 2003; 49(4):650–2. [PubMed: 12651819]
20. Dastani Z, Hivert MF, Timpson N, et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. *PLoS genetics*. 2012; 8(3):29.
21. Heid IM, Henneman P, Hicks A, et al. Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. *Atherosclerosis*. 2010; 208(2):412–20. [PubMed: 20018283]
22. Ling H, Waterworth DM, Stirnadel HA, et al. Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. *Obesity (Silver Spring, Md)*. 2009; 17(4):737–44. DOI: 10.1038/oby.2008.625
23. Richards JB, Waterworth D, O’Rahilly S, et al. A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. *PLoS genetics*. 2009; 5(12):11.

24. He B, Pan Y, Zhang Y, et al. Effects of genetic variations in the adiponectin pathway genes on the risk of colorectal cancer in the Chinese population. *BMC medical genetics*. 2011; 12:94.doi: 10.1186/1471-2350-12-94 [PubMed: 21749709]
25. Kaklamani VG, Wisinski KB, Sadim M, et al. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. *Jama*. 2008; 300(13):1523–31. DOI: 10.1001/jama.300.13.1523 [PubMed: 18827209]
26. Liu L, Zhong R, Wei S, et al. Interactions between genetic variants in the adiponectin, adiponectin receptor 1 and environmental factors on the risk of colorectal cancer. *PloS one*. 2011; 6(11):e27301.doi: 10.1371/journal.pone.0027301 [PubMed: 22087284]
27. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Human molecular genetics*. 2014; 23(R1):R89–98. DOI: 10.1093/hmg/ddu328 [PubMed: 25064373]
28. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. *The American journal of clinical nutrition*. 2016; doi: 10.3945/ajcn.115.118216
29. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. *Econometrica*. 1980; 48(4):817–38.
30. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986; 7(3):177–88. [PubMed: 3802833]
31. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. *Statistical methods in medical research*. 2015; doi: 10.1177/0962280215597579
32. Yang X, Li J, Cai W, et al. Adiponectin Gene Polymorphisms are Associated with Increased Risk of Colorectal Cancer. *Medical science monitor: international medical journal of experimental and clinical research*. 2015; 21:2595–606. DOI: 10.12659/MSM.893472 [PubMed: 26329379]
33. Pei Y, Xu Y, Niu W. Causal relevance of circulating adiponectin with cancer: a meta-analysis implementing Mendelian randomization. *Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2015; 36(2):585–94. DOI: 10.1007/s13277-014-2654-x [PubMed: 25273172]
34. Evans DM, Davey Smith G. Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. *Annual review of genomics and human genetics*. 2015; 16:327–50. DOI: 10.1146/annurev-genom-090314-050016
35. VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P. Methodological challenges in mendelian randomization. *Epidemiology (Cambridge, Mass)*. 2014; 25(3):427–35. DOI: 10.1097/EDE.0000000000000081
36. Dai JY, Zhang XC. Mendelian randomization studies for a continuous exposure under case-control sampling. *American journal of epidemiology*. 2015; 181(6):440–9. DOI: 10.1093/aje/kwu291 [PubMed: 25713335]

Figure 1.

Directed acyclic graph (DAG) for Mendelian Randomization Study on adiponectin and colorectal cancer risk. X: modifiable exposure of interest; Y: outcome; C: confounder(s); Z: instrumental variable. NOTE: The effect of Z on Y should be mediated only through X (no pleiotropy), therefore this line is dashed. Associations [ZX] and [ZY] are used to estimate the causal effect of a biomarker on an outcome circumventing residual confounding and reverse causation.

Table 1

Baseline characteristics of study participants in EPIC, HPFS and NHS

	EPIC (n=1,246) ^a		p ^b	HPFS (n=461) ^a		p ^c	NHS (n=1173) ^a		p ^c
	Controls (n=623)	Cases (n=623)		Controls (n=230)	Cases (n=231)		Controls (n=774)	Cases (n=399)	
Female sex, n (%)	289 (46.4)	289 (46.4)	*	0 (0)	0 (0)		771 (100)	398 (100)	
Age at blood collection, years, mean (SD)	58.3 (8.2)	58.3 (8.2)	*	65.6 (8.9)	66.1 (8.8)	*	59.1 (6.7)	59.2 (6.7)	*
Current smoking, n (%)	124 (19.9)	122 (19.6)	0.88	12 (5.4)	8 (3.6)	0.35	90 (11.7)	48 (12.1)	0.85
Caucasian ethnicity, n (%)	n.a.	n.a.	n.a.	226 (98.3)	219 (94.8)	0.04	773 (99.9)	399 (100)	0.47
Physical activity (MET-hours/week), mean (SD)	89.1 (52.1)	90.4 (54.8)	0.59	34.5 (29.2)	35.8 (41.3)	0.70	16.4 (19.8)	16.5 (19.2)	0.88
Body mass index, kg/m ² , mean (SD)	26.4 (3.8)	27.1 (4.4)	0.001	25.2 (3.3)	26.0 (3.1)	0.004	25.4 (4.4)	25.3 (4.3)	0.72
Waist circumference, cm, mean (SD)	89.3 (12.3)	91.9 (13.1)	<0.0001	94.2 (9.4)	96.8 (8.4)	0.004	79.5 (10.7)	80.3 (10.9)	0.41
Alcohol intake, g/day, median (IQR)	6.4 (1.0–21.1)	7.8 (0.8–22.6)	0.02	7.0 (1.8–15.8)	6.9 (0.9–18.7)	0.86	1.1 (0.0–6.9)	1.8 (0.0–8.5)	0.07
Fiber, g/day, median (IQR)	21.8 (17.7–27.0)	21.5 (16.8–27.5)	0.77	22.7 (18.6–28.8)	22.2 (18.4–27.2)	0.34	18.1 (15.1–21.3)	17.7 (15.2–21.1)	0.34
Red and processed meat, g/day, median (IQR)	69.1 (45.4–101.5)	72.3 (49.4–108.8)	0.02	63.4 (33.5–98.1)	64.5 (37.5–105.5)	0.20	52.4 (33.4–81.2)	55.8 (33.4–91.7)	0.23
Total adiponectin (µg/mL), median (IQR) ^c	6.3 (4.8–8.7)	5.9 (4.3–8.2)	0.01	5.6 (3.9–8.2)	5.3 (3.5–7.2)	0.21	8.5 (6.0–11.0)	8.5 (6.0–11.5)	0.64

SD, standard deviation, IQR, inter-quartile range, MET, metabolic equivalent of task

^aAdiponectin measurement was not available in n=16 controls and n=7 cases in EPIC, in n=63 controls and n=56 cases in HPFS, and in n=264 controls and n=112 cases in NHS; some study participants had missing values for the here displayed diet and lifestyle factors: in EPIC, there were missing values on physical activity (n=69 controls, n=67 cases) and waist circumference (n=65 controls, n=65 cases); in HPFS, there were missing values on smoking status (n=7 controls, n=6 cases), waist circumference (n=25 controls, n=46 cases), alcohol (n=4 controls, n=5 cases), fiber (n=1 case) or red and processed meat (n=4 controls, n=5 cases) intake; in NHS, there were missing values on alcohol (n=8 controls, n=1 cases), fiber (n=11 controls, n=2 cases) and red and processed meat (n=8 controls, n=1 case) intake.

^bp-values for the difference between cases and controls were determined by Mc Nemar's test for variables expressed as %, by student's paired t-test for variables expressed as means, and by Wilcoxon's signed rank test for variables expressed as medians

^cp-values for the difference between cases and controls were determined by Chi²-test for variables expressed as %, analysis of variance (general linear model) for variables expressed as means, and by the non-parametric Kruskal-Wallis test for variables expressed as medians

Table 2

Association between ADIPOQ SNPs genotyped in EPIC, *ADIPOQ* allele score and plasma adiponectin levels in control participants

SNP	Men and women (n=623)					
	MAF	Relative change (95% CI), % ^a	Ptrend	F-Value	R ² (%)	
rs1063539	G>C 13%	0.9 (−6.2; 8.6)	0.81	0.1	0.0	
rs16861194	A>G 8%	−4.4 (−12.9; 4.8)	0.34	1.0	0.2	
rs12495941	G>T 37%	0.1 (−5.0; 5.5)	0.96	0.0	0.0	
rs822391	T>C 19%	5.2 (−1.7; 12.6)	0.14	2.2	0.4	
rs822394	C>A 17%	4.1 (−2.9; 11.6)	0.26	1.3	0.2	
rs17300539 ^b	G>A 9%	18.2 (8.5; 28.8)	<0.0001	14.5	2.3	
rs17366568 ^b	G>A 11%	−12.3 (−19.0; −5.0)	<0.0001	10.3	1.7	
rs17366743	T>C 3%	20.6 (3.0; 41.2)	0.02	5.4	0.9	
rs182052 ^{b, c}	G>A 35%	−2.8 (−7.8; 2.5)	0.29	1.1	0.2	
rs266729 ^b	C>G 27%	−1.6 (−7.1; 4.2)	0.59	0.3	0.1	
rs1501299 ^b	G>T 28%	6.3 (0.3; 12.5)	0.04	4.3	0.7	
rs2241766	T>G 13%	2.3 (−5.1; 10.3)	0.56	0.3	0.1	
rs3774261	G>A 41%	5.3 (0.1; 10.9)	0.05	3.9	0.6	
rs3821799	C>T 47%	0.0 (−4.9; 5.2)	0.99	0.0	0.0	
<i>ADIPOQ</i> allele score		6.5 (3.6; 9.4)	<0.0001	20.2	3.2	

MAF: Minor allele frequency; 95% CI, 95% confidence interval

^aPercent change in adiponectin concentrations per copy of minor allele (effect allele) or score unit, estimated in univariable linear regression models.

^bIncorporated in *ADIPOQ* allele score for EPIC

^cproxy SNP for rs6810075

in bold: statistically significant associations (p<0.05)

Table 3

Association between all ADIPOQ SNPs genotyped in HPFS and NHS, *ADIPOQ* allele score and plasma adiponectin levels in control participants

SNP	Men (n=167), HPFS					Women (n=510), NHS				
	MAF	Rel. change (95% CI), % ^a	Ptrend	F-Value	R ² (%)	SNP	MAF	Rel. change (95% CI), % ^a	Ptrend	F-Value
rs1063539	G>C 15%	-5.6 (-20.0; 11.5)	0.50	0.5	0.3	rs1063539	G>C 12%	-1.4 (-9.4; 7.4)	0.75	0.1
rs16861194	A>G 9%	-1.5 (-19.0; 19.8)	0.88	0.0	0.0	rs16861194	A>G 5%	-9.1 (-19; 1.9)	0.10	2.7
rs7615090	T>G 5%	-7.4 (-29.0; 20.8)	0.57	0.3	0.2	rs7615090	T>G 6%	-7.3 (-18; 4.8)	0.23	1.5
rs822394	C>A 15%	-2.3 (-16.3; 13.9)	0.76	0.1	0.1	rs822394	C>A 17%	6.1 (-1.3; 14.0)	0.11	2.6
rs17300539 ^b	G>A 9%	13.5 (-5.8; 36.6)	0.19	1.8	1.1	rs17300539 ^b	G>A 8%	13.3 (2.8; 25.0)	0.01	6.3
rs17366568 ^b	G>A 8%	-9.7 (-26; 10.1)	0.32	1.0	0.6	rs17366568 ^b	G>A 7%	-18.5 (-26.8; -9.2)	<0.0001	13.8
rs17366743	T>C 3%	0.9 (-26.4; 38.3)	0.96	0.0	0.0	rs17366743	T>C 3%	2.5 (-11.7; 18.9)	0.75	0.1
rs6810075 ^b	T>C 33%	-11.8 (-21.2; -1.2)	0.03	4.6	2.7	rs6810075 ^b	T>C 31%	-5.0 (-10; 0.7)	0.09	3.0
rs6773957	G>A 41%	9.2 (-2.6; 22.3)	0.13	2.3	1.4	rs6773957	G>A 38%	6.5 (0.9; 12.5)	0.02	5.2
rs822354	G>A 36%	7.6 (-4.1; 20.9)	0.22	1.5	0.9	rs822354	G>A 33%	1.4 (-4.2; 7.4)	0.62	0.2
rs6444175	G>A 28%	11.4 (-0.7; 25.0)	0.07	3.3	2.0	rs6444175	G>A 27%	7.6 (1.2; 14.5)	0.02	5.5
rs266717	T>C 49%	-3.2 (-13.3; 8.0)	0.56	0.3	0.2	rs266717	T>C 47%	-3.8 (-8.8; 1.5)	0.16	2.0
rs1426810	A>G 37%	0.7 (-9.8; 12.4)	0.91	0.0	0.0	rs1426810	A>G 40%	3.9 (-1.7; 9.9)	0.17	1.9
rs1342387	T>C 43%	2.9 (-7.9; 15.0)	0.62	0.3	0.2	rs1342387	T>C 45%	-4.4 (-9.5; 1.0)	0.11	2.5
rs12733285	C>T 30%	-2.7 (-13.7; 9.8)	0.66	0.2	0.1	rs12733285	C>T 30%	-4.1 (-9.6; 1.7)	0.16	2.0
rs266729 ^b	C>G 24%	-12.6 (-22.8; -1.2)	0.03	4.6	2.7	rs266729 ^b	C>G 26%	-4.4 (-10; 1.8)	0.16	2.0
rs1501299 ^b	G>T 26%	13.4 (1.0; 27.4)	0.04	4.4	2.6	rs1501299 ^b	G>T 27%	8.6 (2.2; 15.5)	0.01	7.0
rs1063538	C>T 41%	9.2 (-2.6; 22.3)	0.13	2.3	1.4	rs1063538	C>T 38%	6.6 (0.9; 12.5)	0.02	5.2
rs3774262	G>A 15%	-6.0 (-20.0; 10.5)	0.46	0.6	0.3	rs3774262	G>A 11%	-0.7 (-9.0; 8.4)	0.88	0.0
<i>ADIPOQ</i> allele score		7.7 (0.9; 14.9)	0.03	5.0	2.9	<i>ADIPOQ</i> allele score		7.7 (4.1; 11.3)	<0.0001	18.8
										3.6

MAF: Minor allele frequency; 95% CI, 95% confidence interval

^aPercent change in adiponectin concentrations per copy of minor allele (effect allele) or score unit, estimated in univariable linear regression models.^bincorporated in *ADIPOQ* allele score for HPFS/NHS**in bold:** statistically significant associations (p<0.05)

Table 4
Association between *ADIPOQ* allele score and colorectal cancer risk in EPIC, HPFS, and NHS

	No. Cases/No. Controls	Relative change % ^a	OR	(95% CI)	P _{trend}	P _{het.}
EPIC ^b	623/623	6.5	0.95	(0.87, 1.03)	0.23	
HPFS ^c	231/230	7.7	1.00	(0.85, 1.17)	0.97	
NHS ^c	399/774	7.7	0.98	(0.88, 1.09)	0.73	
Pooled	1253/1627		0.97	(0.91, 1.04)	0.43	0.86

^aPer score unit, estimates based on univariate linear regression in controls

^bConditional logistic regression, controlling for matching factors (age at blood collection, study center, fasting status, menopausal status and hormone use in women)

^cUnconditional logistic regression, adjusted for matching factors(age at blood draw, date of blood draw)

OR, odds ratio; 95% CI, 95% confidence interval; p_{het.}, P value for heterogeneity by study

Table 5

Instrumental variable estimation of the association between genetically determined adiponectin concentrations with risk of colorectal cancer in EPIC, HPFS, and NHS (*ADIPOQ* allele score as instrumental variable)

	No. Cases/No. Controls	IV-OR	(95% CI)	P _{trend}	P _{het.}
EPIC	623/623	0.61	(0.25, 1.49)	0.28	
HPFS	231/230	0.90	(0.21, 3.84)	0.89	
NHS	399/774	0.83	(0.31, 2.22)	0.71	
Pooled	1253/1627	0.73	(0.40, 1.34)	0.31	0.86

IV-OR, instrumental variable odds ratio; 95% CI, 95% confidence interval; P_{het.}, P value for heterogeneity by study

IV-OR derived from two-stage regression. First stage was a linear regression. In EPIC, the second stage was a conditional logistic regression controlling for matching factors (age at blood collection, study center, fasting status, menopausal status and hormone use in women); in HPFS and NHS, the second stage was an unconditional logistic regression adjusting for matching factors (age at blood draw, date of blood draw)

P_{het.}, P value for heterogeneity by study